

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation

D Wang,* C Cummins, S Bayliss,
J Sandercock and A Burls

Department of Public Health and Epidemiology, University of Birmingham,
Birmingham, UK

*Corresponding author


Declared competing interests of authors: none



Executive summary

Health Technology Assessment 2008; Vol. 12: No. 36

**Health Technology Assessment
NIHR HTA Programme
www.hta.ac.uk**





Executive summary

Background

Respiratory syncytial virus (RSV) causes outbreaks of respiratory tract infection in the winter months in the UK. It is the leading cause of lower respiratory tract infection (LRTI) in infants and can lead to hospitalisation, particularly in those who are premature or who have chronic lung disease (CLD) or congenital heart disease (CHD). There are currently two licensed specific therapies in the UK: ribavirin and palivizumab. Palivizumab is a monoclonal antibody designed to provide passive immunity against RSV and thereby prevent or reduce the severity of RSV infection. It is licensed for the prevention of serious lower LRTI caused by RSV in children at high risk. While it is recognised that a policy of using palivizumab for all children who meet the licensed indication does not meet conventional UK standards of cost-effectiveness, most clinicians feel that its use is justified in some children. The purpose of this review is to determine if we can identify subgroups in whom palivizumab is cost-effective.

Objective

This review aims to systematically examine the scientific evidence about the effectiveness and cost-effectiveness of palivizumab for the prevention of RSV in children and to look at prognostic factors to determine if it is possible to identify subgroups among which there are important differences in cost-effectiveness.

Methods

We systematically reviewed the literature about the effectiveness and cost-effectiveness of prophylaxis with palivizumab. Bibliographic databases were searched from inception to March 2007 with no date limits or language restrictions. Current economic evaluations were analysed to identify which parameters were driving the different cost-effectiveness estimates. A probabilistic decision-analytical model was built to assess the cost-effectiveness of prophylaxis with palivizumab for children at risk of RSV infection and the parameters populated with the best available

estimate thought to be most applicable to the UK context. Data to inform parameters in our model were systematically sought from the identified trial data and pragmatically identified from observational studies in the wider literature. Meta-analyses were carried out where appropriate.

Results

Clinical effectiveness

Two randomised controlled trials (RCTs) were identified. Prophylaxis with palivizumab for preterm infants without CLD or children with CLD resulted in a 55% reduction in RSV hospital admission: 4.8% (48/1002) in the palivizumab group and 10.6% (53/500) in the no prophylaxis group ($p = 0.0004$).

Prophylaxis with palivizumab was associated with a 45% reduction in RSV hospitalisation rate among children with CHD. Hospitalisation rates for RSV were 5.3% (34/639) in the palivizumab group and 9.7% (63/648) in the no prophylaxis group ($p = 0.003$). A slightly higher mortality in the control group was found in both RCTs, but this was not statistically significant. However, the trials were not powered to demonstrate a difference. Palivizumab had a relatively safe adverse event profile.

Cost-effectiveness

Existing economic evaluations

Three systematic reviews and 18 primary studies were identified. All the systematic reviews stated that the potential costs of palivizumab were far in excess of any likely savings achieved by decreasing hospital admission rates, and that the use of palivizumab was unlikely to be cost-effective in all children for whom it is recommended, but that continued use of palivizumab for particularly high-risk children may be justified. The incremental cost-effectiveness ratios (ICERs) of the primary studies varied 17-fold for life-years gained (LYG), from £25,800/LYG to £404,900/LYG, and several hundred-fold for quality-adjusted life-years (QALYs), from £3200/QALY to £1,489,700/QALY for preterm infants without CLD or children with

CLD. For children with CHD, the ICER varied from £5300/LYG to £7900/LYG and from £7500/QALY to £68,700/QALY.

An analysis of what led to the discrepant ICERs showed that the assumed mortality rate for RSV infection was the most important driver. The rates of hospital and paediatric intensive care unit (PICU) admissions and sequelae of RSV also had measurable effects.

Birmingham Economic Evaluation (BrumEE)

We undertook an independent economic evaluation. The resource use and unit cost were obtained from the trial studies, *British National Formulary* (BNF), Office for National Statistics (ONS), Economic and Social Research Council (ESRC) and previous economic evaluation studies. The utilities were obtained from a UK cohort study. Cost-effectiveness analyses were undertaken from both NHS and societal perspectives. Estimates from an NHS perspective derived using different methods confirm that palivizumab does not reach conventional levels of cost-effectiveness in any of the licensed indications if used for all eligible children – the lowest ICER being £64,000/QALY.

When additional risk factors for RSV hospitalisation derived from observational studies (gestational age, age at the start of the RSV season, having siblings who are in day care or at school) were modelled using the BrumEE, prophylaxis against RSV infection with palivizumab was within the willingness-to-pay threshold of £30,000/QALY in a number of important subgroups of children with CLD. There was insufficient data to undertake a similar risk group analysis for children with CHD.

Conclusion

Prophylaxis with palivizumab is clinically effective for reducing the risk of serious LRTI caused by RSV infection and requiring hospitalisation in high-risk children, but if used unselectively in the licensed population the ICER is over £60,000/QALY, which is double that considered to represent good value for money in the UK (the current willingness-to-pay threshold is about £30,000/QALY). The BrumEE shows that prophylaxis with palivizumab may be cost-effective (based on a threshold of £30,000/QALY, but the threshold for decision-makers may vary, particularly for this type of patient group) for children with CLD when the children have two or more additional risk factors.

Our economic evaluation is limited by the quality and quantity of the primary data available and the pragmatic rather than systematic methods used to identify parameter values. Future research should initially focus on reviewing systematically the major uncertainties for patient subgroups with CLD and CHD (e.g. mortality rates for RSV infection in children not given palivizumab prophylaxis) and then on primary research to address the important uncertainties that remain.

Publication

Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. *Health Technol Assess* 2008;**12**(36).

NIHR Health Technology Assessment Programme

The Health Technology Assessment (HTA) Programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'.

The HTA Programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA Programme then commissions the research by competitive tender.

Second, the HTA Programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Third, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in the widely read journal series *Health Technology Assessment*.

Criteria for inclusion in the HTA journal series

Reports are published in the HTA journal series if (1) they have resulted from work for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this issue of the journal was commissioned by the HTA Programme as project number 06/29/01. The contractual start date was in November 2006. The draft report began editorial review in July 2007 and was accepted for publication in April 2008. As the funder, by devising a commissioning brief, the HTA Programme specified the research question and study design. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme or the Department of Health.

Editor-in-Chief: Professor Tom Walley

Series Editors: Dr Aileen Clarke, Dr Peter Davidson, Dr Chris Hyde, Dr John Powell, Dr Rob Riemsma and Professor Ken Stein

ISSN 1366-5278

© Queen's Printer and Controller of HMSO 2008

This monograph may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.

Applications for commercial reproduction should be addressed to: NCCHTA, Alpha House, Enterprise Road, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk), on behalf of NCCHTA.

Printed on acid-free paper in the UK by the Charlesworth Group.